Teva Pharma Industries Ltd ADR (TEVA) revenue breakdown
By segment, United States is the largest at 53% of fiscal 2025 revenue, growing 9% a year over 3 years.
By product, Sale of Goods is the largest at 85% of fiscal 2025 revenue; Distribution grew fastest, 5% a year over 9 years.
Revenue by segment
Fiscal years, as Teva Pharma Industries Ltd ADR reports them in its 10-K filings; fiscal 2025 total $17.3B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | — | — | — | — | — | $7.0B | $7.7B | $8.0B | $9.2B | 53% |
| Europe | $5.0B | $5.5B | $5.2B | $4.8B | $4.8B | $4.9B | $4.5B | $4.8B | $5.1B | $5.0B | 29% |
| International Markets | $4.0B | $2.9B | $2.4B | $2.2B | $2.2B | $2.0B | $2.4B | $2.4B | $2.5B | $2.2B | 13% |
| Other Activities | $1.1B | $1.4B | $1.4B | $1.3B | $1.3B | $1.2B | $1.0B | $926M | $944M | $870M | 5% |
| North America | $11.8B | $12.1B | $9.3B | $8.5B | $8.4B | $7.8B | — | — | — | — | — |
Revenue by product
Fiscal years, as Teva Pharma Industries Ltd ADR reports them in its 10-K filings; fiscal 2025 total $17.3B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sale of Goods | $20.0B | $19.3B | $15.9B | $14.5B | $14.4B | $13.8B | $12.8B | $13.0B | $14.1B | $14.6B | 85% |
| Distribution | $963M | $1.4B | $1.4B | $1.5B | $1.5B | $1.4B | $1.5B | $1.6B | $1.6B | $1.6B | 9% |
| Licensing Arrangements | $314M | $327M | $165M | $147M | $129M | $160M | $212M | $681M | $173M | $678M | 4% |
| Other | $637M | $886M | $852M | $716M | $680M | $500M | $428M | $570M | $745M | $423M | 2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TEVA.
Open TEVA in InvestinglyQuestions
Where does Teva Pharma Industries Ltd ADR make its money?
In fiscal 2025, by segment: United States $9.2B, Europe $5.0B, International Markets $2.2B, Other Activities $870M.
From Teva Pharma Industries Ltd ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.